Skip to main content

Table 1 Clinical features at baseline and last visit in all PsA patients

From: Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study

 

Baseline

Last visit

P -value

Male gender, n (%)

36 (50.0%)

 

Age, years

49.6 ± 11.7

55.9 ± 11.6

 

Psoriatic arthritis (PsA) characteristics

   

  PsA disease duration, years

9.2 (2.4 to 14.10)

15.7 (8.5 to 21.2)

 

  Tender joint count, 0 to 68

2 (0 to 8)

1 (0 to 4)

0.033

  Swollen joint count, 0 to 66

0 (0 to 3)

0 (0 to 1)

0.032

  Damaged joint count, 0 to 68

2 (0 to 5)

2 (0 to 6)

0.031

  Visual analog scale pain, 0 to 100

50 (30 to 66)

30 (20 to 58)

0.001

  Patients’ global assessment, 0 to 100

50 (30 to 60)

40 (20 to 60)

0.298

  Physicians’ global assessment, 0 to 100

20 (0 to 30)

20 (5 to 35)

0.683

  Psoriasis Area and Severity Index, 0 to 72

2.6 (0.9 to 7.5)

1.8 (0.4 to 6.3)

0.309

  Health assessment questionnaire, 0 to 3

0.38 (0.12 to 0.94)

0.25 (0 to 0.69)

0.043

  Minimal disease activity, n (%)

16 (22.2%)

14 (19.4%)

0.539

  Disease Activity in Psoriatic Arthritis, 0 to 164

16 (8 to 21)

11 (6 to 16)

0.010

  Erythrocyte sedimentation rate, mm/1st h

23 (10 to 37)

18 (8 to 34)

0.357

  C-reactive protein, mg/dl

0.4 (0.2 to 1.3)

0.3 (0.1 to 0.7)

0.016

Cardiovascular risk factors

   

  Body weight, kg

65.2 ± 12.0

65.7 ± 11.6

0.436

  Body height, cm

161 ± 8

 

  Systolic blood pressure, mmHg

136 ± 22

127 ± 15

<0.001

  Hypertension, n (%)

36 (50.0%)

44 (61.1%)

0.555

  Diabetes, n (%)

16 (44.4%)

16 (44.4%)

1.000

  Framingham 10-year CVD risk >10%, n (%)

30 (41.7%)

36 (50.0%)

0.316

  Total cholesterol, mmol/L

5.1 ± 0.9

4.9 ± 0.8

0.073

  High-density lipoprotein cholesterol, mmol/L

1.6 ± 0.5

1.4 ± 0.4

<0.001

  Triglycerides, mmol/L

1.5 ± 0.9

1.5 ± 0.9

0.558

  Fasting glucose, mmol/L

5.5 ± 1.3

5.5 ± 1.6

0.861

Medications, n (%)

   

  Anti-hypertensive drugs

20 (27.8%)

42 (58.3%)

<0.001

  Statins

1 (1.4%)

14 (19.4%)

<0.001

  Nonsteroidal anti-inflammatory drugs

33 (45.8%)

31 (43.1%)

0.737

  Steroids

4 (5.6%)

3 (4.2%)

0.999

  Disease-modifying antirheumatic drugs

36 (50.0%)

40 (55.6%)

0.504

  Biologics

0 (0%)

11 (15.4%)

0.001

  1. Values are presented as number (percentage), median (interquatile range) or mean ± SD. CVD, cardiovascular disease.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us